All Stories

  1. Medical Comorbidity and Male Sex Are Associated With Higher In-hospital Mortality for 90-Day Readmissions and Higher Readmission Rates After Nonelective Primary Total Hip Arthroplasty for Hip Fracture
  2. Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 U.S. rheumatology clinics
  3. Hospital and Patient Factors Associated With Length of Hospitalization in Patients Who Have Osteoarthritis Undergoing Primary Total Knee Arthroplasty: An Analysis of National Data
  4. Rheumatoid Arthritis and the risk of 90-day readmission after hospitalization for heart failure
  5. Are there rural–urban disparities in cardiovascular disease hospitalization and other outcomes in people with gout? A nationwide U.S. study
  6. Association of Patient Sex With Inpatient Mortality After Elective Primary Total Hip Arthroplasty for Osteoarthritis
  7. Geography, neighborhoods and mortality in rheumatic diseases
  8. Barriers to and facilitators of sustaining a systemic lupus erythematosus (SLE) patient decision aid in regular rheumatology outpatient care in the USA
  9. Women undergoing primary total hip arthroplasty (THA) for hip fracture have lower in-hospital mortality compared to men
  10. Rituximab Treatment in Adult Patients With Idiopathic Inflammatory Myositis
  11. Gout Flare Burden in the United States: A Multiyear Cross‐Sectional Survey Study
  12. Long‐Term Mortality Following SARS‐CoV‐2 Infection in Rural Versus Urban Dwellers With Autoimmune or Inflammatory Rheumatic Disease: A Retrospective Cohort Analysis From the National COVID Cohort Collaborative
  13. Clinic personnel attitudes and baseline implementation outcomes of a lupus decision aid
  14. 90-day readmission risk, but not in-hospital mortality is lower in female patients who undergo elective primary total hip arthroplasty for osteoarthritis
  15. Controversies and practical management of patients with gout and chronic kidney disease
  16. Association between diabetes mellitus and total hip arthroplasty outcomes: an observational study using the US National Inpatient Sample
  17. Patient Perspectives on a Decision Aid for Systemic Lupus Erythematosus: Insights and Future Considerations
  18. Osteoarthritis across Joint Sites in the Million Veteran Program: Insights from Electronic Health Records and Military Service History
  19. Weight Loss for Patients With Gout and Concomitant Obesity: A Proof‐of‐Concept Randomized Trial
  20. Contraception Care Patterns for Adult Females With Juvenile Idiopathic Arthritis on Teratogens in the Rheumatology Informatics System for Effectiveness (RISE) Registry
  21. Real‐World Treatment and Care Patterns in Patients With Rheumatoid Arthritis Initiating First‐Line Tumor Necrosis Factor Inhibitor Therapy in the United States
  22. The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases
  23. Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C)
  24. Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout
  25. Identifying physician-perceived barriers to a pragmatic treatment trial in rheumatoid arthritis
  26. Treatment Guidelines in Rheumatoid Arthritis
  27. Racial Differences in XO (Xanthine Oxidase) and Mitochondrial DNA Damage-Associated Molecular Patterns in Resistant Hypertension
  28. Patient Empowerment Among Adults With Arthritis: The Case for Emotional Support
  29. Risks and Benefits of Janus Kinase Inhibitors in Rheumatoid Arthritis — Past, Present, and Future
  30. Time-Trends in Hospitalizations with Cannabis use Disorder: A 17-Year U.S. National Study
  31. Disease modification in gout: a qualitative study of gout expert rheumatologists
  32. Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials
  33. Gout management and outcomes during established COVID-19 pandemic in 2020–2021: a cross-sectional Internet survey
  34. Epidemiology of hospitalizations with cocaine use disorder: A 17-year U.S. national study
  35. Recent health-related quality of life, but not change, predicted mortality and healthcare utilization
  36. SToRytelliing to Improve Disease outcomes in Gout (STRIDE-GO) in African American veterans with gout: a trial study protocol
  37. “I wish it had a place to go”: a nominal group study of barriers to the effectiveness of non-surgical treatments for knee osteoarthritis inclusive of minority populations
  38. Declining in-hospital mortality in vasculitis: A 17-year US national study
  39. SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout
  40. Epidemiology, Time Trends, and Outcomes of Serious Infections in Patients With Vasculitis: A Nineteen‐Year National Study
  41. Time trends in in-hospital mortality reduction in vasculitis vs. non-vasculitis hospitalisations vary by patient sex and age
  42. Higher Serum Urate Levels Are Associated With an Increased Risk for Sudden Cardiac Death
  43. Serious Infections in Patients With Gout in the US: A National Study of Incidence, Time Trends, and Outcomes
  44. Time trends in hospitalizations with anxiolytic, sedative, or hypnotic drug use disorder: a 17-year U.S. national study
  45. Epidemiology of hospitalizations with hallucinogen use disorder: a 17-year U.S. National study
  46. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout
  47. Comment on: Dual-energy computed tomography versus ultrasound, alone or combined, for the diagnosis of gout: a prospective study of accuracy: reply
  48. Time-trends in cocaine, hallucinogen, amphetamine, and sedative/anxiolytic/hypnotic use disorder hospitalizations in rheumatic diseases: a national time-trends study
  49. Implementing the DEcision-Aid for Lupus (IDEAL): study protocol of a multi-site implementation trial with observational, case study design
  50. Comment on: Cannabis use assessment and its impact on pain in rheumatologic diseases: a systematic review and meta-analysis
  51. How do dietary interventions affect serum urate and gout?
  52. Dual-energy computed tomography vs ultrasound, alone or combined, for the diagnosis of gout: a prospective study of accuracy
  53. In-hospital mortality reduction in systemic lupus erythematosus over 2 decades varied by patient sex and age
  54. Traitement anti-TNF ou non anti-TNF dans la polyarthrite rhumatoïde active : facteurs déterminant le choix des patients
  55. Epidemiology of cardiac or orthopedic procedures in gout versus rheumatoid arthritis: a national time-trends study
  56. Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis
  57. Patient Perspectives on Gout and Gout Treatments: A Patient Panel Discussion That Informed the 2020 American College of Rheumatology Treatment Guideline
  58. The death rate Difference between Lupus and non-lupus Hospitalizations is declining
  59. Hospitalized Infections in Lupus: A Nationwide Study of Types of Infections, Time‐trends, Healthcare Utilization and In‐Hospital Mortality
  60. Reasons for hospitalizations for non-gout reasons and mortality in people with gout are changing
  61. Management of Rheumatic Diseases During the COVID‐19 pandemic: A National Veterans Affairs Survey of Rheumatologists
  62. Time Trends in Opioid Use Disorder Hospitalizations in Gout, Rheumatoid Arthritis, Fibromyalgia, Osteoarthritis, and Low Back Pain
  63. Shared decision-making in gout treatment: a national study of rheumatology provider opinion and practice
  64. Which factors predict discordance between a patient and physician on a gout flare?
  65. Hospitalized Infections in People With Osteoarthritis: A National US Study
  66. Sjogren’s syndrome is associated with higher rate of non-home discharge after primary hip arthroplasty and higher transfusion rates after primary hip or knee arthroplasty: a U.S. cohort study
  67. Sjogren’s Syndrome is associated with higher healthcare utilization after primary hip, but not primary knee arthroplasty: A U.S. cohort study
  68. Juvenile idiopathic arthritis is associated with higher healthcare utilization after total knee or hip replacement
  69. Response to: ‘Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland’ by Quills et al
  70. Pop a pill or give myself a shot? Patient perspectives of disease-modifying anti-rheumatic drug choice for rheumatoid arthritis
  71. Serious infections in people with systemic sclerosis: a national US study
  72. Allopurinol versus febuxostat hypersensitivity reactions in the US elderly: differences in study outcomes and populations. Response to: ‘Correspondence to “Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims da...
  73. Hypersensitivity reactions with allopurinol versus febuxostat in the US elderly. Response to: ‘Confunding by indication and ethnicity difference? Comment on ‘Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims ...
  74. Identifying Physician-perceived Barriers to Apragmatictreatment Trial Inrheumatoid Arthritis
  75. Patient, physiotherapist and surgeon endorsement of the core domain set for total hip and total knee replacement in Germany: a study protocol for an OMERACT initiative
  76. Serious infections in people with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA): a time-trend national US study
  77. Serious Infections in People with Systemic sclerosis: A National U.S. Study
  78. Spondyloarthritis is associated with higher healthcare utilization and complication rates after primary total knee or total hip arthroplasty
  79. Sjogren’s Syndrome is associated with higher healthcare utilization after primary hip, but not primary knee arthroplasty: A U.S. cohort study
  80. Acute kidney injury after primary total hip arthroplasty: a risk multiplier for complication, mortality, and healthcare utilization
  81. National U.S. time-trends in opioid use disorder hospitalizations and associated healthcare utilization and mortality
  82. Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data
  83. Serious Infections in People with Scleroderma: A National U.S. Study
  84. Examining Timeliness of Total Knee Replacement Among Patients with Knee Osteoarthritis in the U.S.
  85. Polymyositis has minimal effect on primary total knee or hip arthroplasty outcomes
  86. Acute kidney injury is associated with increased healthcare utilization, complications, and mortality after primary total knee arthroplasty
  87. Diagnostic accuracy of salivary gland ultrasound in Sjögren’s syndrome: A systematic review and meta-analysis
  88. Gout management and outcomes during the COVID-19 pandemic: a cross-sectional internet survey
  89. Age, race, comorbidity, and insurance payer type are associated with outcomes after total ankle arthroplasty
  90. A Personalized Decision Aid to Help Women with Lupus Nephritis from Racially and Ethnically Diverse Backgrounds Make Decisions about Taking Immune-Blocking Medicines
  91. How Systemic Sclerosis Affects Healthcare Use and Complication Rates after Total Hip Arthroplasty
  92. Systemic sclerosis is associated with knee arthroplasty outcomes: a National US study
  93. Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort
  94. Are the days of missed or delayed diagnosis of gout over?
  95. Correction to: Gout and healthcare utilization and complications after hip arthroplasty: a cohort study using the US National Inpatient Sample (NIS)
  96. Factors influencing implementation of a computerized, individualized, culturally tailored lupus decision aid in lupus clinics: a qualitative semi-structured interview study
  97. Insurance Payer Type and Patient Income Are Associated with Outcomes after Total Shoulder Arthroplasty
  98. Total knee arthroplasty outcomes in lupus: a study using the US National Inpatient Sample
  99. Lupus is associated with poorer outcomes after primary total hip arthroplasty
  100. Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial
  101. Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?
  102. Gout and chronic pain in older adults: a Medicare claims study
  103. Allopurinol compared to febuxostat for the risk of atrial fibrillation
  104. Gout is associated with a higher risk of chronic renal disease in older adults: a retrospective cohort study of U.S. Medicare population
  105. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy
  106. The association of gout with incident giant cell arteritis in older adults
  107. Gout and sexual function: patient perspective of how gout affects personal relationships and intimacy
  108. Gout is associated with increased healthcare utilization after knee arthroplasty
  109. Self-reported sleep quality and sleep disorders in people with physician-diagnosed gout: an Internet cross-sectional survey
  110. Gout and healthcare utilization and complications after hip arthroplasty: a cohort study using the US National Inpatient Sample (NIS)
  111. The Third Biennial 2018 OMERACT First-time Participant Program: A Qualitative and Quantitative Study
  112. A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3×3 Methodology Applied to Two Active Comparator Trials
  113. Gout and the risk of Parkinson’s disease in older adults: a study of U.S. Medicare data
  114. Is there a role for cherries in the management of gout?
  115. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
  116. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
  117. Effectiveness of healthcare educational and behavioral interventions to improve gout outcomes: a systematic review and meta-analysis
  118. Gout and dementia in the elderly: a cohort study of Medicare claims
  119. Is Rheumatoid Arthritis a Cardiovascular Risk-Equivalent to Diabetes Mellitus?
  120. Tapering Janus kinase inhibitors in rheumatoid arthritis with low disease activity or remission: reality or dream?
  121. Goals of gout treatment: a patient perspective
  122. Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis
  123. Gout and hearing impairment in the elderly: a retrospective cohort study using the US Medicare claims data
  124. Gout and the risk of age-related macular degeneration in the elderly
  125. Gout and the risk of incident atrial fibrillation in older adults: a study of US Medicare data
  126. Gout and the risk of myocardial infarction in older adults: a study of Medicare recipients
  127. Development of the American College of Rheumatology Electronic Clinical Quality Measures for Gout
  128. Medication adherence among patients with gout: A systematic review and meta-analysis
  129. Any sleep is a dream far away: a nominal group study assessing how gout affects sleep
  130. Septic Arthritis in Emergency Departments in the US : A National Study of Health Care Utilization and Time Trends
  131. The risk of polymyalgia rheumatica in older adults with gout: a Medicare claims study
  132. Taking an Interdisciplinary Approach to Understanding and Improving Medication Adherence
  133. Patients and surgeons provide endorsement of core domains for total joint replacement clinical trials
  134. Validation of a definition for flare in patients with established gout
  135. Shoulder replacement surgery for osteoarthritis and rotator cuff tear arthropathy
  136. Response to: ‘Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults’ by Lee and Song
  137. Weight loss for overweight patients with knee or hip osteoarthritis
  138. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report
  139. Patient-Reported Outcomes Can Be Used to Streamline Post-Total Hip Arthroplasty Follow-Up to High-Risk Patients
  140. Correction to: Adaptation of the 2015 American College of Rheumatology treatment guideline for rheumatoid arthritis for the Eastern Mediterranean Region: an exemplar of the GRADE Adolopment
  141. Is gout a risk equivalent to diabetes for stroke and myocardial infarction? A retrospective claims database study
  142. Considering health equity when moving from evidence-based guideline recommendations to implementation: a case study from an upper-middle income country on the GRADE approach
  143. GRADE equity guidelines 1: considering health equity in GRADE guideline development: introduction and rationale
  144. GRADE equity guidelines 2: considering health equity in GRADE guideline development: equity extension of the guideline development checklist
  145. GRADE equity guidelines 3: considering health equity in GRADE guideline development: rating the certainty of synthesized evidence
  146. GRADE equity guidelines 4: considering health equity in GRADE guideline development: evidence to decision process
  147. Patient Burden of Axial Spondyloarthritis
  148. Response to: ’A response to Singh. “Lesinurad combination therapy with allopurinol in gout: do CLEAR studies make the treatment of gout clearer?”' by Valiyil and Schechter
  149. Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults
  150. Gout Self-Management in African American Veterans: A Qualitative Exploration of Challenges and Solutions From Patients' Perspectives
  151. Role of serum urate in neurocognitive function and dementia: new evidence contradicts old thinking
  152. Adaptation of the 2015 American College of Rheumatology treatment guideline for rheumatoid arthritis for the Eastern Mediterranean Region: an exemplar of the GRADE Adolopment
  153. Gout and comorbidity: a nominal group study of people with gout
  154. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies
  155. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
  156. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  157. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  158. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  159. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016
  160. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
  161. The burden of septic arthritis on the U.S. inpatient care: A national study
  162. Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis
  163. Calcium Pyrophosphate Deposition Disease and Associated Medical Comorbidities: A National Cross-Sectional Study of US Veterans
  164. Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study
  165. The burden of mental disorders in the Eastern Mediterranean region, 1990–2015: findings from the global burden of disease 2015 study
  166. Adolescent health in the Eastern Mediterranean Region: findings from the global burden of disease 2015 study
  167. Burden of cardiovascular diseases in the Eastern Mediterranean Region, 1990–2015: findings from the Global Burden of Disease 2015 study
  168. Burden of lower respiratory infections in the Eastern Mediterranean Region between 1990 and 2015: findings from the Global Burden of Disease 2015 study
  169. Burden of obesity in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study
  170. Trends in HIV/AIDS morbidity and mortality in Eastern Mediterranean countries, 1990–2015: findings from the Global Burden of Disease 2015 study
  171. Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets
  172. Validating Rheumatoid Arthritis Remission Using the Patients’ Perspective: Results from a Special Interest Group at OMERACT 2016
  173. Health Effects of Overweight and Obesity in 195 Countries over 25 Years
  174. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015
  175. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
  176. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
  177. Clinical Practice Guidelines: Incorporating Input From a Patient Panel
  178. Management of Gout
  179. Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data
  180. Child and Adolescent Health From 1990 to 2015
  181. Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials
  182. Receipt of Pain Management Information Preoperatively Is Associated With Improved Functional Gain After Elective Total Joint Arthroplasty
  183. Health care utilization in patients with gout: a prospective multicenter cohort study
  184. Do outcomes reported in randomised controlled trials of joint replacement surgery fulfil the OMERACT 2.0 Filter? A review of the 2008 and 2013 literature
  185. Outcome Measures Used in Arthroplasty Trials: Systematic Review of the 2008 and 2013 Literature
  186. The OMERACT First-time Participant Program: Fresh Eye from the New Guys
  187. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis
  188. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015
  189. Evaluation and Management of the Patient With Suspected Inflammatory Spine Disease
  190. Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data
  191. Patient Endorsement of the Outcome Measures in Rheumatology (OMERACT) Total Joint Replacement (TJR) clinical trial draft core domain set
  192. Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes
  193. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis
  194. Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection
  195. Burden of musculoskeletal disorders in the Eastern Mediterranean Region, 1990–2013: findings from the Global Burden of Disease Study 2013
  196. Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group
  197. Low-dose SoluMatrix diclofenac in patients with osteoarthritis pain: impact on quality of life in a controlled trial
  198. Individualized patient decision-aid for immunosuppressive drugs in women with lupus nephritis: study protocol of a randomized, controlled trial
  199. Consensus on draft OMERACT core domains for clinical trials of Total Joint Replacement outcome by orthopaedic surgeons: a report from the International consensus on outcome measures in TJR trials (I-COMiTT) group
  200. Achieving Consensus on Total Joint Replacement Trial Outcome Reporting Using the OMERACT Filter: Endorsement of the Final Core Domain Set for Total Hip and Total Knee Replacement Trials for Endstage Arthritis
  201. Cytokine and neuropeptide levels are associated with pain relief in patients with chronically painful total knee arthroplasty: a pilot study
  202. An underlying diagnosis of osteonecrosis of bone is associated with worse outcomes than osteoarthritis after total hip arthroplasty
  203. Lesinurad combination therapy with allopurinol in gout: do CLEAR studies make the treatment of gout clearer?
  204. Chasing crystals out of the body: will treat to serum urate target for gout help us get there?
  205. The Association of Vibratory Perception and Muscle Strength With the Incidence and Worsening of Knee Instability: The Multicenter Osteoarthritis Study
  206. Mapping Perceptions of Lupus Medication Decision-Making Facilitators: The Importance of Patient Context
  207. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA)
  208. Gout: will the “King of Diseases” be the first rheumatic disease to be cured?
  209. Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures
  210. Racial differences in health-related quality of life and functional ability in patients with gout
  211. Increasing comorbidity is associated with worsening physical function and pain after primary total knee arthroplasty
  212. Successful Stepwise Development of Patient Research Partnership: 14 Years’ Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT)
  213. Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
  214. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
  215. Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015
  216. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015
  217. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
  218. Does T'ai Chi Gait Reduce External Knee Adduction Moment?
  219. Allopurinol reduces the risk of myocardial infarction (MI) in the elderly: a study of Medicare claims
  220. Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis
  221. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis
  222. Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies
  223. Allopurinol and the risk of stroke in older adults receiving medicare
  224. Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015
  225. Correction to Lancet HIV 2016; 3: e361–87
  226. Assessment of physical function and participation in chronic pain clinical trials
  227. Treatments for Lupus Nephritis: A Systematic Review and Network Metaanalysis
  228. Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis
  229. Renal dosing of allopurinol results in suboptimal gout care
  230. Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination
  231. How often is the office visit needed? Predicting total knee arthroplasty revision risk using pain/function scores
  232. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015
  233. Emergency Department and Inpatient Healthcare utilization due to Hypertension
  234. Development of gellan gum containing formulations for transdermal drug delivery: Component evaluation and controlled drug release using temperature responsive nanogels
  235. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines
  236. Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure
  237. Clinically important improvement thresholds for Harris Hip Score and its ability to predict revision risk after primary total hip arthroplasty
  238. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis
  239. Allopurinol treatment of gout and the risk of heart rhythm problem in elderly
  240. Do pessimists report worse outcomes after total hip arthroplasty?
  241. Time Trends, Predictors, and Outcome of Emergency Department Use for Gout: A Nationwide US Study
  242. Reply
  243. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises
  244. Regional analgesia versus no regional analgesia for ambulatory hip arthroscopy in adults
  245. The Global Burden of Anemia
  246. Ms. A.M. Taylor, et al reply
  247. Racial/Ethnic Disparity in Rates and Outcomes of Total Joint Arthroplasty
  248. Cervical cancer risk with the use of tumour necrosis factor inhibitors in rheumatoid arthritis: to worry or not to worry?
  249. Gout-related inpatient utilization: a study of predictors of outcomes and time trends
  250. A cross-sectional internet-based patient survey of the management strategies for gout
  251. Performance of Gout Impact Scale in a longitudinal observational study of patients with gout
  252. Reply
  253. Development of the GRADE Evidence to Decision (EtD) frameworks for tests in clinical practice and public health
  254. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis
  255. Validation of the Mayo Hip Score: construct validity, reliability and responsiveness to change
  256. Utilization due to chronic obstructive pulmonary disease and its predictors: a study using the U.S. National Emergency Department Sample (NEDS)
  257. PROMs for Gouty Arthritis
  258. Depression and Anxiety following Coronary Artery Bypass Graft: Current Indian Scenario
  259. 10.1016/S0140-6736(15)60692-4
  260. A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database
  261. Minorities with lupus nephritis and medications: a study of facilitators to medication decision-making
  262. Current tobacco use is associated with higher rates of implant revision and deep infection after total hip or knee arthroplasty: a prospective cohort study
  263. When Patients Write the Guidelines: Patient Panel Recommendations for the Treatment of Rheumatoid Arthritis
  264. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
  265. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
  266. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition
  267. Racial Disparities In total ankle arthroplasty Utilization and outcomes
  268. Age-related differences in the use of total shoulder arthroplasty over time: use and outcomes
  269. Serum urate gene associations with incident gout, measured in the Framingham Heart Study, are modified by renal disease and not by body mass index
  270. Do “Evidence-Based Recommendations” Need to Reveal the Evidence? Minimal Criteria Supporting an “Evidence Claim”
  271. A Call for Evidence-based Decision Making When Selecting Outcome Measurement Instruments for Summary of Findings Tables in Systematic Reviews: Results from an OMERACT Working Group
  272. Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda
  273. 2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
  274. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
  275. Erratum to: Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
  276. Validity and sensitivity to change of three scales for the radiographic assessment of knee osteoarthritis using images from the Multicenter Osteoarthritis Study (MOST)
  277. Persisting Racial Disparities in Total Shoulder Arthroplasty Utilization and Outcomes
  278. Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists
  279. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
  280. Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musculoskeletal Group and OMERACT
  281. Barriers to Medication Decision Making in Women with Lupus Nephritis: A Formative Study using Nominal Group Technique
  282. The Global Burden of Cancer 2013
  283. Is Chronic Pain a Disease in Its Own Right? Discussions from a Pre-OMERACT 2014 Workshop on Chronic Pain
  284. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis
  285. Total joint replacement surgery for knee osteoarthritis and other non-traumatic diseases: a network meta-analysis
  286. Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures
  287. Investigational drugs for hyperuricemia
  288. Subcutaneous or intramuscular methotrexate for rheumatoid arthritis
  289. Validation of Administrative Codes for Calcium Pyrophosphate Deposition
  290. An Internet Survey of Common Treatments Used by Patients With Gout Including Cherry Extract and Juice and Other Dietary Supplements
  291. The OMERACT First-time Participant (“Newbie”) Program: Initial Assessment and Lessons Learned
  292. Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study
  293. Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop
  294. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
  295. Does Hospital Volume Predict Outcomes and Complications After Total Shoulder Arthroplasty in the US?
  296. Consensus on the Need for a Hierarchical List of Patient-reported Pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective
  297. Rheumatoid Arthritis is Associated With Higher Ninety-Day Hospital Readmission Rates Compared to Osteoarthritis After Hip or Knee Arthroplasty: A Cohort Study
  298. TNF-alpha inhibitors for ankylosing spondylitis
  299. Muscle inflammation susceptibility: a prognostic index of recovery potential after hip arthroplasty?
  300. Are There Modifiable Risk Factors for Hospital Readmission After Total Hip Arthroplasty in a US Healthcare System?
  301. Outcome Domains and Measures in Total Joint Replacement Clinical Trials: Can We Harmonize Them? An OMERACT Collaborative Initiative
  302. Are there racial disparities in utilization and outcomes after total elbow arthroplasty?
  303. Nerve blocks or no nerve blocks for pain control after elective hip replacement (arthroplasty) surgery in adults
  304. Racial disparities in total ankle arthroplasty utilization and outcomes
  305. Regional analgesia versus no regional analgesia for ambulatory hip arthroscopy in adults
  306. Does rural residence impact total ankle arthroplasty utilization and outcomes?
  307. Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance)
  308. Is the Double Contour Sign Specific for Gout? Or Only for Crystal Arthritis?
  309. Exercise therapy following surgical rotator cuff repair
  310. Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working Group
  311. Chondroitin for osteoarthritis
  312. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration
  313. When gout goes to the heart: does gout equal a cardiovascular disease risk factor?
  314. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
  315. Dependence on Walking Aids and Patient-Reported Outcomes after Total Knee Arthroplasty
  316. Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials
  317. Patient-centered priorities for improving medication management and adherence
  318. Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales
  319. Patient-centered interventions to improve medication management and adherence: A qualitative review of research findings
  320. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)
  321. Trends in and disparities for acute myocardial infarction: an analysis of Medicare claims data from 1992 to 2010
  322. Remembering the forgotten non-communicable diseases
  323. Sex differences in characteristics, utilization, and outcomes of patient undergoing total elbow arthroplasty: a study of the US nationwide inpatient sample
  324. Impaired response or insufficient dosage?—Examining the potential causes of “inadequate response” to allopurinol in the treatment of gout
  325. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials
  326. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis
  327. Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
  328. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
  329. Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
  330. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013
  331. Bariatric Surgery Prior to Total Joint Arthroplasty May Not Provide Dramatic Improvements in Post-Arthroplasty Surgical Outcomes
  332. Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0
  333. Methotrexate use and liver disease - a causal relationship?
  334. Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis
  335. Time trends in total ankle arthroplasty in the USA: a study of the National Inpatient Sample
  336. Time Trends in the Characteristics of Patients Undergoing Primary Total Knee Arthroplasty
  337. Comorbidities in Patients with Crystal Diseases and Hyperuricemia
  338. Faculty of 1000 evaluation for Surgery versus physical therapy for a meniscal tear and osteoarthritis.
  339. Challenges Faced by Patients in Gout Treatment
  340. Updating the OMERACT Filter: Discrimination and Feasibility
  341. Updating the OMERACT Filter: Implications of Filter 2.0 to Select Outcome Instruments Through Assessment of “Truth”: Content, Face, and Construct Validity
  342. Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets
  343. Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: an update
  344. How to Choose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Approves Filter 2.0
  345. Research Priorities in Gout: The Patient Perspective
  346. Updating the OMERACT Filter: Implications for Imaging and Soluble Biomarkers
  347. Editorial: Arthroplasty Outcomes Are Improving, but Why Isn't My Patient With Rheumatoid Arthritis Doing as Well?
  348. Predictors of pain medication use for arthroplasty pain after revision total knee arthroplasty
  349. Application of the OMERACT Filter to Measures of Core Outcome Domains in Recent Clinical Studies of Acute Gout
  350. Reliability and Clinically Important Improvement Thresholds for Osteoarthritis Pain and Function Scales: A Multicenter Study
  351. Cerebrovascular Disease Is Associated with Outcomes After Total Knee Arthroplasty: A US Total Joint Registry Study
  352. The impact of gout on patient’s lives: a study of African-American and Caucasian men and women with gout
  353. Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
  354. Trends in and disparities for acute myocardial infarction: an analysis of Medicare claims data from 1992 to 2010
  355. Depression in primary TKA and higher medical comorbidities in revision TKA are associated with suboptimal subjective improvement in knee function
  356. Are outcomes after total knee arthroplasty worsening over time? A time-trends study of activity limitation and pain outcomes
  357. Increasing obesity and comorbidity in patients undergoing primary total hip arthroplasty in the U.S.: A 13-year study of time trends
  358. Patient-Centered Outcomes Research Institute (PCORI) multisite project to develop treatment decision aids for racial/ethnic minorities with lupus nephritis
  359. OMERACT 11: International Consensus Conference on Outcome Measures in Rheumatology
  360. OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout
  361. Outcome Measures in Acute Gout: A Systematic Literature Review
  362. Update of Strategies to Translate Evidence from Cochrane Musculoskeletal Group Systematic Reviews for Use by Various Audiences
  363. Does Clinically Important Change in Function After Knee Replacement Guarantee Good Absolute Function? The Multicenter Osteoarthritis Study
  364. Updated Method Guidelines for Cochrane Musculoskeletal Group Systematic Reviews and Metaanalyses
  365. Better Functional and Similar Pain Outcomes in Osteoarthritis Compared to Rheumatoid Arthritis After Primary Total Knee Arthroplasty: A Cohort Study
  366. Ofatumumab for rheumatoid arthritis
  367. Diabetes: A Risk Factor for Poor Functional Outcome after Total Knee Arthroplasty
  368. Underlying diagnosis predicts patient-reported outcomes after revision total knee arthroplasty
  369. Patient-level improvements in pain and activities of daily living after total knee arthroplasty
  370. Including Health Equity Considerations in Development of Instruments for Rheumatology Research: An Introduction to a Novel OMERACT Paradigm
  371. Racial disparities in knee and hip total joint arthroplasty: an 18-year analysis of national medicare data
  372. Total joint replacement surgery versus conservative care for knee osteoarthritis and other non-traumatic diseases
  373. Total hip replacement surgery versus conservative care for hip osteoarthritis and other non-traumatic diseases
  374. The State of US Health, 1990-2010
  375. Medical Comorbidity is Associated with Persistent Index Hip Pain after Total Hip Arthroplasty
  376. Perioperative interventions for smoking cessation in hip and knee arthroplasty for osteoarthritis and other non-traumatic diseases
  377. Belimumab for systemic lupus erythematosus
  378. Use of botulinum toxin in musculoskeletal pain
  379. Folic Acid Supplementation for Rheumatoid Arthritis Patients on Methotrexate: The Good Gets Better
  380. Acquired supravalvular pulmonary stenosis due to extrinsic compression by a mediastinal dermoid cyst
  381. Sex and Surgical Outcomes and Mortality After Primary Total Knee Arthroplasty: A Risk‐Adjusted Analysis
  382. Participation Following Knee Replacement: The MOST Cohort Study
  383. Using tablet computers compared to interactive voice response to improve subject recruitment in osteoporosis pragmatic clinical trials: feasibility, satisfaction, and sample size
  384. The Influence of the Contralateral Knee Prior to Knee Arthroplasty on Post-Arthroplasty Function
  385. Reply
  386. Clinically Important Body Weight Gain Following Knee Arthroplasty: A Five-Year Comparative Cohort Study
  387. The relation between cancer patient treatment decision-making roles and quality of life
  388. Gout-Related Health Care Utilization in US Emergency Departments, 2006 Through 2008
  389. Income and patient-reported outcomes (PROs) after primary total knee arthroplasty
  390. Use of biologics in a patient with rheumatoid arthritis refractory to methotrexate
  391. Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature
  392. Use of botulinum toxin in musculoskeletal pain
  393. Botox for Joints
  394. Crystal arthritis: Is HLAB genotyping the future of gout pharmacogenomics?
  395. Patient-level clinically meaningful improvements in activities of daily living and pain after total hip arthroplasty: data from a large US institutional registry
  396. Faculty of 1000 evaluation for Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
  397. Medical and psychological comorbidity predicts poor pain outcomes after total knee arthroplasty
  398. Predictors of periprosthetic fracture after total knee replacement
  399. Ipsilateral lower extremity joint involvement increases the risk of poor pain and function outcomes after hip or knee arthroplasty
  400. Veterans Affairs databases are accurate for gout-related health care utilization: a validation study
  401. Operative diagnosis for revision total hip arthroplasty is associated with patient-reported outcomes (PROs)
  402. Are Gender, Comorbidity, and Obesity Risk Factors for Postoperative Periprosthetic Fractures After Primary Total Hip Arthroplasty?
  403. Patients with osteoarthritis and avascular necrosis have better functional outcomes and those with avascular necrosis worse pain outcomes compared to rheumatoid arthritis after primary hip arthroplasty: a cohort study
  404. Clinically important body weight gain following total hip arthroplasty: a cohort study with 5-year follow-up
  405. Mediation of smoking-associated postoperative mortality by perioperative complications in veterans undergoing elective surgery: data from Veterans Affairs Surgical Quality Improvement Program (VASQIP)—a cohort study
  406. Racial and Gender Disparities Among Patients with Gout
  407. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
  408. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
  409. Emerging therapies for gout
  410. Periprosthetic infections after total shoulder arthroplasty: a 33-year perspective
  411. Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States
  412. Periprosthetic Fractures Associated with Primary Total Shoulder Arthroplasty and Primary Humeral Head Replacement
  413. Total Knee Arthroplasty in Morbidly Obese Patients Treated With Bariatric Surgery
  414. Periprosthetic infections after shoulder hemiarthroplasty
  415. Reply
  416. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia
  417. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis
  418. Total Knee Arthroplasty Volume, Utilization, and Outcomes Among Medicare Beneficiaries, 1991-2010
  419. Patient Factors Predict Periprosthetic Fractures After Revision Total Hip Arthroplasty
  420. Ninety-day Mortality in Patients Undergoing Elective Total Hip or Total Knee Arthroplasty
  421. Peptic ulcer disease and heart disease are associated with periprosthetic fractures after total hip replacement
  422. Risk factors for revision surgery after humeral head replacement: 1,431 shoulders over 3 decades
  423. Improved Health-related Quality of Life and Physical Function in Patients with Refractory Chronic Gout Following Treatment with Pegloticase: Evidence from Phase III Randomized Controlled Trials
  424. Stem cells and other innovative intra-articular therapies for osteoarthritis: what does the future hold?
  425. Summary of AHRQ’s Comparative Effectiveness Review of Drug Therapy for Rheumatoid Arthritis (RA) in Adults – An Update
  426. Developing a provisional definition of flare in patients with established gout
  427. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
  428. Cardiopulmonary Complications After Primary Shoulder Arthroplasty: A Cohort Study
  429. Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor
  430. Can racial disparities in optimal gout treatment be reduced? evidence from a randomized trial
  431. A systematic review of validated methods for identifying orthopedic implant removal and revision using administrative data
  432. Quality of Care in Gout
  433. Predictors of use of pain medications for persistent knee pain after primary Total Knee Arthroplasty: a cohort study using an institutional joint registry
  434. The Attributable Risk of Smoking on Surgical Complications
  435. Adverse Effects of Smoking on Postoperative Outcomes in Cancer Patients
  436. Revision surgery following total shoulder arthroplasty: Analysis of 2588 shoulders over three decades (1976 to 2008)
  437. Gouty Arthritis
  438. Cardiac and thromboembolic complications and mortality in patients undergoing total hip and total knee arthroplasty
  439. Comparison of Patient-Reported and Clinician-Assessed Outcomes Following Total Knee Arthroplasty
  440. Association of peptic ulcer disease and pulmonary disease with risk of periprosthetic fracture after primary total knee arthroplasty
  441. Smoking as a risk factor for short-term outcomes following primary total hip and total knee replacement in veterans
  442. Hospital volume and surgical outcomes after elective hip/knee arthroplasty: A risk-adjusted analysis of a large regional database
  443. Developing a Construct to Evaluate Flares in Rheumatoid Arthritis: A Conceptual Report of the OMERACT RA Flare Definition Working Group: Table 1.
  444. OARSI/OMERACT Initiative to Define States of Severity and Indication for Joint Replacement in Hip and Knee Osteoarthritis. An OMERACT 10 Special Interest Group
  445. OMERACT 10 Patient Perspective Virtual Campus: Valuing Health; Measuring Outcomes in Rheumatoid Arthritis Fatigue, RA Sleep, Arthroplasty, and Systemic Sclerosis; and Clinical Significance of Changes in Health
  446. Biologicals for rheumatoid arthritis
  447. Bringing It All Together: A Novel Approach to the Development of Response Criteria for Chronic Gout Clinical Trials
  448. Early Postoperative Mortality Following Joint Arthroplasty: A Systematic Review
  449. Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial
  450. Patient-reported Outcomes in Chronic Gout: A Report from OMERACT 10
  451. Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology?
  452. Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities
  453. Patient understanding and satisfaction in informed consent for total knee arthroplasty: A randomized study
  454. Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care
  455. Health Care Utilization in Patients with Gout
  456. Smoking and Outcomes After Knee and Hip Arthroplasty: A Systematic Review
  457. Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials
  458. Responsiveness differences in outcome instruments after revision hip arthroplasty: What are the implications?
  459. Higher Body Mass Index Is Not Associated With Worse Pain Outcomes After Primary or Revision Total Knee Arthroplasty
  460. Editorial - Current Concepts in Arthroplasty§
  461. Epidemiology of Knee and Hip Arthroplasty: A Systematic Review§
  462. Diagnosis and Management of Infected Total Knee Arthroplasty§
  463. Biomarkers in Arthroplasty: A Systematic Review
  464. Minimally important differences of the gout impact scale in a randomized controlled trial
  465. Adverse effects of biologics: a network meta-analysis and Cochrane overview
  466. Risk factors for gout and prevention: a systematic review of the literature
  467. Botulinum Toxin for Shoulder Pain: A Cochrane Systematic Review
  468. The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement
  469. Surgery for Shoulder Osteoarthritis: A Cochrane Systematic Review
  470. Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis
  471. Ninety day mortality and its predictors after primary shoulder arthroplasty: an analysis of 4,019 patients from 1976-2008
  472. Predictors of Activity Limitation and Dependence on Walking Aids After Primary Total Hip Arthroplasty
  473. Accuracy of VA databases for diagnoses of knee replacement and hip replacement
  474. Extramediastinal thymolipomas—challenges in diagnosis and dilemmas in approaches: a review
  475. Tocilizumab for Rheumatoid Arthritis: A Cochrane Systematic Review
  476. Surgery for shoulder osteoarthritis
  477. Adverse effects of biologics: a network meta-analysis and Cochrane overview
  478. Predictors of Moderate-Severe Functional Limitation 2 and 5 Years After Revision Total Knee Arthroplasty
  479. A Population-Based Study of Trends in the Use of Total Hip and Total Knee Arthroplasty, 1969-2008
  480. Botulinum toxin for shoulder pain
  481. Gout in the Hmong in the United States
  482. Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial
  483. Predictors of doctor-rated and patient-rated gout severity: gout impact scales improve assessment
  484. Tocilizumab for rheumatoid arthritis
  485. Pessimistic explanatory style: A PSYCHOLOGICAL RISK FACTOR FOR POOR PAIN AND FUNCTIONAL OUTCOMES TWO YEARS AFTER KNEE REPLACEMENT
  486. Golimumab for Rheumatoid Arthritis: A Systematic Review
  487. Efficacy of Intra-Articular Botulinum Toxin Type A in Painful Knee Osteoarthritis: A Pilot Study
  488. Predictors of moderate–severe functional limitation after primary Total Knee Arthroplasty (TKA): 4701 TKAs at 2-years and 2935 TKAs at 5-years
  489. Pegloticase for chronic gout
  490. A national survey of Veterans Affairs Rheumatologists for relevance of quality of care indicators for Gout management
  491. Abatacept for Rheumatoid Arthritis: A Cochrane Systematic Review
  492. Trial sample size, but not trial quality, is associated with positive study outcome
  493. Challenges With Health-related Quality of Life Assessment in Arthroplasty Patients: Problems and Solutions
  494. Golimumab for rheumatoid arthritis
  495. Tocilizumab for rheumatoid arthritis
  496. Pegloticase for chronic gout
  497. Botulinum toxin for shoulder pain
  498. Abatacept for Rheumatoid Arthritis: A Cochrane Systematic Review
  499. Botulinum toxin therapy for osteoarticular pain: an evidence-based review
  500. Newer Biological Agents in Rheumatoid Arthritis
  501. Applying science in practice: the optimization of biological therapy in rheumatoid arthritis
  502. Predictors of pain and use of pain medications following primary Total Hip Arthroplasty (THA): 5,707 THAs at 2-years and 3,289 THAs at 5-years
  503. Advances in gout: some answers, more questions
  504. Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases
  505. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
  506. Assessment of the Methodologic Quality of Medical and Surgical Clinical Trials in Patients with Arthroplasty
  507. Surgery for shoulder osteoarthritis
  508. Biologics for rheumatoid arthritis: an overview of Cochrane reviews
  509. Abatacept for rheumatoid arthritis
  510. Intra-articular Botulinum Toxin Type A: A new approach to treat arthritis joint pain
  511. Outcome Domains for Studies of Acute and Chronic Gout
  512. Progress in Measurement Instruments for Acute and Chronic Gout Studies
  513. Mobile and Fixed-Bearing (All-Polyethylene Tibial Component) Total Knee Arthroplasty Designs
  514. Variation in Outcome Measures in Hip and Knee Arthroplasty Clinical Trials: A Proposed Approach to Achieving Consensus
  515. Age, gender, obesity, and depression are associated with patient-related pain and function outcome after revision total hip arthroplasty
  516. Discordance Between Self-report of Physician Diagnosis and Administrative Database Diagnosis of Arthritis and Its Predictors
  517. Higher comorbidity, poor functional status and higher health care utilization in veterans with prevalent total knee arthroplasty or total hip arthroplasty
  518. The Establishment of the GENEQOL Consortium to Investigate the Genetic Disposition of Patient-Reported Quality-of-Life Outcomes
  519. Effect of comorbidity on quality of life of male veterans with prevalent primary total knee arthroplasty
  520. Anakinra for Rheumatoid Arthritis: A Systematic Review
  521. Effect of resistance exercise on bone mineral density in premenopausal women
  522. Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial
  523. Effet des exercices de renforcement musculaire sur la densité minérale osseuse chez les femmes en période de préménopause
  524. Biologics for rheumatoid arthritis: an overview of Cochrane reviews
  525. Spondyloarthritis Is Associated with Poor Function and Physical Health-Related Quality of Life
  526. Toward a valid definition of gout flare: Results of consensus exercises using delphi methodology and cognitive mapping
  527. Quality of life and quality of care for patients with gout
  528. Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: A report of two cases
  529. Utilisation de la toxine A botulique en intra-articulaire pour douleur résistante locales chez des polyarthrites rhumatoïdes traitées par biothérapies : deux observations
  530. Anakinra for rheumatoid arthritis
  531. Health-Related Quality of Life in Rheumatoid Arthritis
  532. Health Care Costs in Gout
  533. Repeat Injections of Intra-Articular Botulinum Toxin A for the Treatment of Chronic Arthritis Joint Pain
  534. Botulinum Toxin for Osteoarticular Pain
  535. Perceptions of disease and health-related quality of life among patients with gout
  536. Can patients help with long-term total knee arthroplasty surveillance? Comparison of the American Knee Society Score self-report and surgeon assessment
  537. O1 Opportunities for improving medication use and monitoring in gout
  538. Health care utilization in patients with spondyloarthropathies
  539. Evaluation of an Instrument Assessing Influence of Gout on Health-Related Quality of Life
  540. Health-related quality of life in veterans with prevalent total knee arthroplasty and total hip arthroplasty
  541. Chronic Constrictive Calcific Pericarditis
  542. Opportunities for improving medication use and monitoring in gout
  543. The Impact of Gender, Age, and Preoperative Pain Severity on Pain After TKA
  544. Abatacept for rheumatoid arthritis
  545. Anakinra for rheumatoid arthritis
  546. Surgical Management of Aortic Stenosis in a Child
  547. Age and Sex are Predictors of Moderate to Severe Pain Post Total Knee Arthroplasty
  548. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout
  549. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans
  550. Assessment of outcome in clinical trials of gout a review of current measures
  551. The effects of intra-articular botulinum toxin on sacroiliac, cervical/lumbar facet and sterno-clavicular joint pain and C-2 root and lumbar disc pain: a case series of 11 patients
  552. Effect of Health-Related Quality of Life on Women and Men’s Veterans Affairs (VA) Health Care Utilization and Mortality
  553. Contributions of OMERACT to rheumatic disease research
  554. Accuracy of the diagnoses of spondylarthritides in veterans affairs medical center databases
  555. Classification criteria in rheumatic diseases: A review of methodologic properties
  556. Absence of histologic evidence of synovitis in patients with Gulf War veterans' illness with joint pain
  557. Quality of care for gout in the US needs improvement
  558. Spondyloarthropathy: An Independent Risk Factor for Kidney Stones
  559. Antibiotics for reactive arthritis
  560. Development of classification and response criteria for rheumatic diseases
  561. Long term effects of intra-articular botulinum toxin a for refractory joint pain
  562. Chondroitin for osteoarthritis
  563. Use of breath carbon monoxide measurements to assess erythrocyte survival in subjects with chronic diseases
  564. Health-related quality of life predicts future health care utilization and mortality in veterans with self-reported physician-diagnosed arthritis: The veterans arthritis quality of life study
  565. Cardiac magnetic resonance imaging abnormalities in systemic lupus erythematosus: a preliminary report
  566. Opioid use by patients in an orthopedics spine clinic
  567. Health-Related Quality of Life, Functional Impairment, and Healthcare Utilization by Veterans: Veterans' Quality of Life Study
  568. Accuracy of veterans administration databases for a diagnosis of rheumatoid arthritis
  569. Poster 7 intra-articular botulinum toxin type A for refractory joint pain. Maren L. Mahowald, MD (Minneapolis VA Med Ctr/Univ Minnesota, Minneapolis, MN); Jasvinder A. Singh, MD, MPH; Dennis D. Dykstra, MD, PhD, e-mail: mahow001@umn.edu
  570. Immunohistochemistry of normal human knee synovium: a quantitative study
  571. Leflunomide use during the first 33 months after food and drug administration approval: Experience with a national cohort of 3,325 patients
  572. Talo-patello-scaphoid osteolysis, synovitis, and short fourth metacarpals in sisters: A new syndrome?
  573. Ciprofloxacin-Related Acute Peripheral Neuropathy in a Patient With Lupus Nephritis
  574. Pulmonary Takayasu???s Arteritis Masquerading as Acute Pulmonary Embolism
  575. Synthesis of 2-Methylheptadecane and 14-Methylpentadecan-3-one
  576. The use of botulinum neurotoxin in musculoskeletal pain and arthritis
  577. Gender and Arthroplasty Type Affect Prevalence of Moderate-Severe Pain Post Total Hip Arthroplasty